Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Valentina E. Schneeberger 1,2 , Yuan Ren 1 , Noreen Luetteke 3 , Qingling Huang 1 , Liwei Chen 1 , Harshani R. Lawrence 4 , Nicholas J. Lawrence 4,5 , Eric B. Haura 5,6 , John M. Koomen 1,2,5 , Domenico Coppola 5,7 and Jie Wu 1,2,5 1 Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 2 Division of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida, USA 3 Small Animal Modeling and Imaging Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 4 Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 5 Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, Florida, USA 6 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 7 Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA Correspondence: Jie Wu, email: // Keywords : Shp2, EGFR, phosphatase, transgenic mice, lung cancer Received : October 07, 2014 Accepted : January 13, 2015 Published : January 31, 2015 Abstract Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and are targeted for therapy. However, resistance to EGFR inhibitors has been observed, in which the mutant EGFR remains active. Thus, it is important to uncover mediators of EGFR mutant-driven lung tumors to develop new treatment strategies. The protein tyrosine phosphatase (PTP) Shp2 mediates EGF signaling. Nevertheless, it is unclear if Shp2 is activated by oncogenic EGFR mutants in lung carcinoma or if inhibiting the Shp2 PTP activity can suppress EGFR mutant-induced lung adenocarcinoma. Here, we generated transgenic mice containing a doxycycline (Dox)-inducible PTP-defective Shp2 mutant (tetO-Shp2CSDA). Using the rat Clara cell secretory protein (CCSP)-rtTA-directed transgene expression in the type II lung pneumocytes of transgenic mice, we found that the Gab1-Shp2 pathway was activated by EGFR L858R in the lungs of transgenic mice. Consistently, the Gab1-Shp2 pathway was activated in human lung adenocarcinoma cells containing mutant EGFR. Importantly, Shp2CSDA inhibited EGFR L858R -induced lung adenocarcinoma in transgenic animals. Analysis of lung tissues showed that Shp2CSDA suppressed Gab1 tyrosine phosphorylation and Gab1-Shp2 association, suggesting that Shp2 modulates a positive feedback loop to regulate its own activity. These results show that inhibition of the Shp2 PTP activity impairs mutant EGFR signaling and suppresses EGFR L858R -driven lung adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 3×
“Approximately 80% of EGFR mutations in non-small cell lung cancer (NSCLC) are either deletion of the conserved four amino acids LREA residues in exon 19 or a L858R point mutation in exon 21 [18].”
BackgroundSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“EGFR is the second most frequently mutated oncogene in lung adenocarcinoma after KRAS [15].”
BackgroundSelf-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · cited 2×
“Therefore, it is necessary to develop new EGFR PTK inhibitors and/or to target additional tumor promoting molecules to improve lung cancer treatment [18, 21, 22].”
BackgroundNovel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · cited 1×
“WZ4002 was reported to inhibit the EGFR T790M mutant [23].”
BackgroundSelf-citationBentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478 · cited 4×
“A, Diagrams of the tetO-Shp2CSDA, tetO-EGFRL858R [19] and CCSP-rtTA [25] transgenes of mice used in this study.”
BackgroundMethodInfluentialJi, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Self-citationAraki, T., Nawa, H., & Neel, B. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306461200 · Cited by 231 · cited 1×
“However, it has reported that EGFR does not phosphorylate Shp2 C-terminal tyrosine residues well and the potential Y542 phosphorylation mediated docking function only plays a peripheral, if any, role in EGFR signaling [29].”
Background
Cited by
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
“Irrespective of the mode of activation, multiple lines of evidence suggest that PTPN11/Shp2 inactivation can suppress tumorigenesis (Aceto et al., 2012; Prahallad et al., 2015; Ren et al., 2010; Schneeberger et al., 2015), making it among the highest priority PTP targets for anticancer drug development (Ostman et al.”
BackgroundSelf-citationMutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Metadata
- Authors
- Schneeberger, V. E., Ren, Y., Luetteke, N., Huang, Q., Chen, L., Lawrence, H. R., Lawrence, N. J., Haura, E. B., Koomen, J. M., Coppola, D., & Wu, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-01-31
- Volume
- 6
- Issue
- 8
- Pages
- 6191-6202
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1546685097
- Cited by
- 47
- References
- 8
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. https://app.cochat.ai/papers/10.18632/oncotarget.3356
- The paper
- Schneeberger, V. E., Ren, Y., Luetteke, N., Huang, Q., Chen, L., Lawrence, H. R., Lawrence, N. J., Haura, E. B., Koomen, J. M., Coppola, D., & Wu, J. (2015). Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.3356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.